New: Introducing the Finviz Crypto Map

Learn More
Last Close
Jul 31 04:00PM ET
0.2555
Dollar change
-0.0237
Percentage change
-8.49
%
Index- P/E- EPS (ttm)-0.47 Insider Own51.33% Shs Outstand162.39M Perf Week-21.53%
Market Cap59.01M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float112.40M Perf Month-6.07%
Enterprise Value64.41M PEG- EPS next Q- Inst Own9.50% Short Float1.16% Perf Quarter-28.97%
Income-74.78M P/S- EPS this Y- Inst Trans-0.77% Short Ratio0.36 Perf Half Y-66.52%
Sales0.00M P/B0.47 EPS next Y- ROA-50.56% Short Interest1.31M Perf YTD-69.42%
Book/sh0.54 P/C36.20 EPS next 5Y- ROE-67.13% 52W High2.10 -87.83% Perf Year-78.26%
Cash/sh0.01 P/FCF- EPS past 3/5Y-16.97% -13.58% ROIC-84.13% 52W Low0.26 -3.22% Perf 3Y-88.23%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.50% 10.40% Perf 5Y-93.53%
Dividend TTM- EV/Sales- EPS Y/Y TTM58.00% Oper. Margin- ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.13 Sales Y/Y TTM- Profit Margin- RSI (14)37.68 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.13 EPS Q/Q100.22% SMA20-15.28% Beta0.53 Target Price-
Payout- Debt/Eq0.08 Sales Q/Q- SMA50-19.20% Rel Volume0.52 Prev Close0.28
Employees25 LT Debt/Eq0.01 Earnings- SMA200-59.34% Avg Volume3.64M Price0.26
IPOFeb 02, 2015 Option/ShortYes / Yes EPS/Sales Surpr.- - Trades Volume1,884,422 Change-8.49%
Jul-29-25 03:01PM
Jul-28-25 10:38AM
Jul-17-25 09:15AM
Jul-09-25 08:00AM
Jun-30-25 09:21AM
11:13AM Loading…
Jun-10-25 11:13AM
Jun-03-25 09:15AM
May-23-25 09:17AM
May-22-25 09:41PM
03:12PM
11:05AM
May-14-25 09:15AM
May-13-25 09:15AM
Apr-22-25 09:20AM
Apr-09-25 09:25AM
12:10PM Loading…
Apr-05-25 12:10PM
Apr-04-25 09:40AM
Mar-03-25 09:15AM
09:00AM
Feb-26-25 01:25PM
09:15AM
Feb-19-25 10:10AM
Jan-07-25 09:15AM
09:15AM
Jan-06-25 09:15AM
09:10AM
Dec-30-24 09:00AM
Dec-23-24 09:00AM
Dec-20-24 03:40PM
09:00AM
08:31AM Loading…
Nov-04-24 08:31AM
Oct-17-24 09:15AM
Oct-16-24 09:28AM
Sep-19-24 09:00AM
Sep-17-24 09:00AM
Sep-13-24 09:00AM
Sep-11-24 09:15AM
Jul-26-24 07:36AM
05:30AM
Jun-14-24 09:06AM
May-24-24 09:20AM
08:45AM
May-16-24 08:53AM
Apr-30-24 11:00AM
Apr-24-24 09:00AM
Apr-18-24 08:45AM
Mar-04-24 09:00PM
Feb-15-24 09:25AM
Feb-14-24 10:01AM
Feb-13-24 09:46AM
09:31AM
Jan-25-24 12:45PM
Jan-18-24 09:30AM
Jan-16-24 08:00AM
Nov-28-23 08:30AM
Nov-23-23 09:30AM
Nov-22-23 10:44AM
Nov-21-23 08:30AM
Nov-14-23 09:00AM
Nov-10-23 08:30AM
Nov-07-23 08:30AM
Oct-24-23 09:00AM
Oct-11-23 09:25AM
08:30AM
Oct-10-23 08:00AM
Oct-04-23 09:00AM
Oct-02-23 12:05PM
09:25AM
08:30AM
Sep-29-23 09:15AM
09:15AM
Sep-21-23 03:00PM
Sep-19-23 08:30AM
Sep-06-23 12:40AM
Aug-30-23 09:15AM
Aug-21-23 09:15AM
Aug-10-23 12:06AM
Aug-09-23 09:00AM
Jul-17-23 07:29AM
Jun-23-23 05:00PM
Jun-08-23 08:45AM
Apr-03-23 09:00AM
Mar-29-23 09:00AM
Mar-13-23 08:30AM
Feb-23-23 04:04PM
Nov-30-22 05:20PM
Oct-26-22 12:01AM
Oct-24-22 08:11PM
08:00AM
Oct-21-22 05:00PM
Oct-17-22 08:30AM
Sep-01-22 08:08AM
Jul-25-22 10:15AM
Jul-01-22 08:37PM
05:00PM
Jun-27-22 03:00PM
Jun-10-22 04:00PM
Jun-09-22 05:59PM
May-31-22 08:00AM
May-25-22 04:20PM
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.